Conservative approach in localised rhabdomyosarcoma of the bladder and prostate: Results from International Society of Paediatric Oncology (SIOP) studies: Malignant mesenchymal tumour (MMT) 84, 89 and 95
- 29 August 2013
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (2) , 217-222
Abstract
Background The three sequential SIOP MMT studies provide the largest dataset available to date, to define the patient and tumour characteristics, treatment modalities and event‐free and overall survival for children with non metastatic rhabdomyosarcoma (RMS) of the bladder and/or prostate (BP). Procedure The combined dataset of 172 patients with BP RMS treated on the SIOP MMT 84, 89 and 95 studies was reviewed to determine tumour characteristics, details of treatment and outcome. Results Median age at diagnosis was 2.5 years (range 2 months–17.8 years) and 138 (79%) were males. Median follow‐up was 11.4 years (range 3 months–22 years). The 5‐year overall survival of the combined cohort was 77% (CI 70–83%). The 5‐year event‐free survival was 63% and included 7 patients (4%) who did not achieve complete remission (CR), and 57 (33%) who relapsed. Age ≥ 10 years (RR 3.7) and alveolar pathology (RR 3.3) were identified as independent prognostic factors on multivariate analysis. Fifty‐nine (50%) of the 119 survivors were cured without significant local therapy, improving from 31% in MMT84 study to 61% in MMT95 study. Conclusion The clinical strategy of the MMT studies aims to minimise the burden of therapy whilst maintaining survival rates. Overall survival is comparable to that of other international groups, despite the lower use of radiotherapy and or radical surgery, although number of events experienced is higher. Further assessment of the late effects of therapy is required to confirm whether this approach results in lower morbidity in the long‐term. Pediatr Blood Cancer 2014;61:217–222.Keywords
Funding Information
- Institut Gustave Roussy
- Villejuif, Société Française des Cancers et Leucémies de l'Enfant et de l'Adolescent
- Association Enfants et Santé
This publication has 18 references indexed in Scilit:
- Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue Sarcomas: Long-Term Results From the International Society of Pediatric Oncology MMT95 StudyJournal of Clinical Oncology, 2012
- Conservative surgery plus brachytherapy treatment for boys with prostate and/or bladder neck rhabdomyosarcoma: a single team experienceJournal of Pediatric Surgery, 2009
- Treatment of Nonmetastatic Rhabdomyosarcoma in Childhood and Adolescence: Third Study of the International Society of Paediatric Oncology—SIOP Malignant Mesenchymal Tumor 89Journal of Clinical Oncology, 2005
- Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic DiseaseJournal of Clinical Oncology, 2001
- Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84European Journal of Cancer, 1998
- Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification-an intergroup rhabdomyosarcoma studyCancer, 1995
- An attempt to use a common staging system in rhabdomyosarcoma: A report of an international workshop initiated by the international society of pediatric oncology (SIOP)Medical and Pediatric Oncology, 1989
- Histopathological classification of childhood rhabdomyosarcoma: A report from the international society of pediatric oncology pathology panelMedical and Pediatric Oncology, 1989
- Primary chemotherapy in the treatment of rhabdomyosarcoma in children: Trial of the international society of pediatric oncology (SIOP) preliminary resultsRadiotherapy and Oncology, 1985
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958